Price T Rowe Associates Inc Anavex Life Sciences Corp. Transaction History

Price T Rowe Associates Inc

$812 Billion
Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 33,039 shares of AVXL stock, worth $248,783. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,039

Previous 29,197 13.16%

Holding current value

$248,783

Previous $314,000 9.55%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$7.85 - $13.46 $30,159 - $51,713	3,842 Added 13.16%	33,039 $284,000
Q4 2024 Feb 14, 2025	SELL	$5.11 - $12.56 $173,290 - $425,934	-33,912 Reduced 53.74%	29,197 $314,000
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $38,280 - $65,570	9,314 Added 17.31%	63,109 $359,000
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $6,851 - $10,145	2,021 Added 3.9%	53,795 $228,000
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $4,304 - $6,385	946 Added 1.86%	51,774 $264,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $6,647 - $13,124	1,319 Added 2.66%	50,828 $474,000
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $40,217 - $57,531	6,140 Added 14.16%	49,509 $325,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $6,702 - $8,312	875 Added 2.06%	43,369 $353,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $3,552 - $5,017	427 Added 1.02%	42,494 $365,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $4,788 - $9,033	626 Added 1.51%	42,067 $390,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $39,872 - $57,612	4,480 Added 12.12%	41,441 $428,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $3,720 - $6,535	509 Added 1.4%	36,961 $370,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $46,235 - $83,974	4,747 Added 14.97%	36,452 $449,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $11,208 - $15,477	664 Added 2.14%	31,705 $550,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $166,518 - $254,925	9,900 Added 46.83%	31,041 $557,000
Q2 2021 Aug 16, 2021	SELL	$10.16 - $28.86 $5,090 - $14,458	-501 Reduced 2.31%	21,141 $483,000
Q1 2021 May 17, 2021	SELL	$5.17 - $16.13 $229,289 - $715,365	-44,350 Reduced 67.21%	21,642 $324,000
Q4 2020 Feb 16, 2021	BUY	$4.01 - $7.58 $264,627 - $500,219	65,992 New	65,992 $356,000

Others Institutions Holding AVXL

# of Institutions

203

Shares Held

31M

Call Options Held

1.3M

Put Options Held

662K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $587M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Anavex Life Sciences Corp. Transaction History